Covid-19 Research

Special Issue

Next-Gen Oncology: Biomarkers, Immunotherapy, and Clinical Translation

A JBRES Special Issue dedicated to rigorous, outcome-oriented advances in oncology—linking biomarker discovery, next-generation immunotherapy, precision strategies, and clinical translation to improve cancer care and patient outcomes.

Home › Special Issues › Next-Gen Oncology
Submit Manuscript All Special Issues
JBRES Special Issue • Cancer & Oncology Research
Special Issue Title

Next-Gen Oncology: Biomarkers, Immunotherapy, and Clinical Translation

This Special Issue of the Journal of Biomedical Research & Environmental Sciences (JBRES) invites high-quality submissions that strengthen the evidence base for next-generation oncology. We welcome work that advances biomarker discovery & validation, develops novel immunotherapies, and demonstrates clinical translation & real-world effectiveness across diverse cancer types and patient populations.

Biomarkers & Precision
Predictive/prognostic markers, companion diagnostics, multi-omics, liquid biopsy (ctDNA), TMB/MSI, PD-L1, AI-driven tools.
Immunotherapy & Translation
Checkpoint inhibitors, CAR-T/TCR/TIL therapies, bispecifics, ADCs, combinations, resistance reversal, implementation in practice.
Submit to This Special Issue Submission Guidelines Peer Review Policy

About this Special Issue

Oncology research is strongest when it connects biomarker insights with therapeutic innovation and practical outcomes. This Special Issue focuses on next-generation oncology—from precision biomarkers and advanced immunotherapies to resistance mechanisms, combination strategies, and policy-relevant translation. We especially welcome submissions that report transparent methods, robust endpoints, and insights that can improve survival, equity, and long-term cancer care.

Preference is given to studies with clear outcomes (ORR, PFS, OS, irAEs), robust analysis, and a concise “What this changes in practice” statement.

Topics of interest

Submissions may address (but are not limited to):

Cancer Biomarkers & Diagnostics Immune Checkpoint Inhibitors CAR-T Cell & Adoptive Therapies Tumor Mutational Burden & MSI Liquid Biopsy & ctDNA Monitoring Resistance Mechanisms in Immunotherapy Combination Therapies & ADCs Precision Oncology Approaches Immunotherapy in Solid & Liquid Tumors Real-World Evidence & Outcomes Toxicity & Immune-Related Adverse Events Translational & Biomarker-Driven Trials

Article types accepted

  • Original Research Articles
  • Clinical Trials & Intervention Studies
  • Observational & Population Studies
  • Review Articles
  • Systematic Reviews & Meta-Analyses
  • Mini-Reviews
  • Short Communications
  • Case Studies (where appropriate)
Tip: Include (1) primary/secondary outcomes, (2) a brief methods transparency note (preregistration/data availability if applicable), and (3) a “Clinical Relevance” paragraph.

Why submit to this Special Issue?

  • Therapy-forward visibility: your work is presented alongside next-gen oncology and immunotherapy research.
  • Efficient editorial pathway: JBRES targets rapid peer review (7–14 days where applicable).
  • Permanent DOI: accepted articles receive DOI for strong citation continuity.
  • Open access reach: broad discoverability for clinicians, researchers, and oncology teams.
  • Author support: clear guidance through review, proofing, and publication.
Ready to submit?
Submit online, or share an abstract for an editorial scope check (methods + outcomes summary preferred).
Submit Manuscript Email Abstract
Submission Portal Submission Instructions Aims & Scope Archive
Alternative submission emails: [email protected] | [email protected]
License (upon publication): Creative Commons CC BY 4.0
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership